SHINGRIX (HERPES ZOSTER VACCINE RECOMBINANT, ADJUVANTED)

Your severely immunocompromised (IC) patient may now be eligible for a SHINGRIX vaccination under the National Immunisation Programme1

The Shingles National Immunisation Programme expanded on the 1st September 20231

UKHSA has declared that severely immunosuppressed individuals represent the highest priority for vaccination given their risk of severe disease, and therefore the programme aims to catch up all eligible individuals aged 50 years and over in the first year of programme implementation1

Could your patient benefit from a referral into primary care to ensure they don't miss their opportunity to be vaccinated?

Find out if your severely IC patient is eligible*

*Based on the Green Book, chapter 28a eligibility criteria

Is your severely IC patient...

Does your patient...

Your patient may be eligible if...

  • They have acute and chronic leukaemias, and clinically aggressive lymphomas (including Hodgkin’s lymphoma) that are less than 12 months since achieving cure
  • They are under follow up for chronic lymphoproliferative disorders including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias (N.B: this list not exhaustive)
  • They have immunosuppression due to HIV/AIDS with a current CD4 count of below 200 cells/μl.
  • They have primary or acquired cellular and combined immune deficiencies – those with lymphopaenia (<1,000 lymphocytes/ul) or with a functional lymphocyte disorder
  • They have received an allogeneic (cells from a donor) or an autologous (using their own cells) stem cell transplant in the previous 24 months
  • They have received a stem cell transplant more than 24 months ago but have ongoing immunosuppression or graft versus host disease (GVHD)

Your patient may be eligible if...

  • They are receiving or have received in the past 6 months immunosuppressive chemotherapy or radiotherapy for any indication
  • They are receiving or have received in the previous 6 months immunosuppressive therapy for a solid organ transplant
  • They are receiving or have received in the previous 3 months targeted therapy for autoimmune disease, such as JAK inhibitors or biologic immune modulators, including:
  • B-cell targeted therapies (including rituximab but for which a 6 month period should be considered immunosuppressive), monoclonal tumor necrosis factor inhibitors (TNFi), T-cell co-stimulation modulators, soluble TNF receptors, interleukin (IL)-6 receptor inhibitors.,
  • IL-17 inhibitors, IL 12/23 inhibitors, IL 23 inhibitors (N.B: this list is not exhaustive)

Your patient may be eligible if...

  • They are receiving or have received moderate to high dose corticosteroids (equivalent ≥20mg prednisolone per day) for more than 10 days in the previous month
  • They are receiving or have received long term moderate dose corticosteroids (equivalent to ≥10mg prednisolone per day for more than 4 weeks) in the previous 3 months
  • They are receiving or have received any non-biological oral immune modulating drugs e.g. methotrexate >20mg per week (oral and subcutaneous), azathioprine >3.0mg/kg/day; 6-mercaptopurine >1.5mg/kg/day, mycophenolate >1g/day) in the previous 3 months
  • They are receiving or have received certain combination therapies at individual doses lower than stated above, including those on ≥7.5mg prednisolone per day in combination with other immunosuppressants (other than hydroxychloroquine or sulfasalazine) and those receiving methotrexate (any dose) with leflunomide in the previous 3 months

Your patient may be eligible

Your patient may be eligible if...

  • They are receiving a stem cell transplant (allogenic transplant or autologous transplant)
  • They are receiving CAR-T (chimeric antigen receptor T-Cell) therapy

When should my eligible severely immunocompromised patients receive their SHINGRIX vaccination?

  • Eligible individuals who have not previously been vaccinated should commence a course of SHINGRIX at the earliest opportunity and at least 14 days before starting immunosuppressive therapy.1

  • SHINGRIX is given as a 2 dose schedule. The national guidance for administration of the second dose as part of the national immunisation programme differs from the SmPC.*

*Please refer to your local guidelines for further information on dosing

Learn more about SHINGRIX

IMPACT OF SHINGLES

What is the impact of shingles on IC patients?

There is a 1 in 4 lifetime risk of developing shingles in the general population. IC patients are at increased risk of shingles and its complications compared to the general population1

IMPACT OF SHINGLES

clinical trial data in IC patients

Learn more about SHINGRIX clinical trial data on IC patients

SHINGRIX has been investigated in a range of immunocompromised (IC) patient populations over/ equal 18 years of age including solid tumours, haematologic malignancies, renal transplants and autologous haematopoietic stem cell transplants (auHSCT), includes post-hoc analyses.4-8

clinical trial data in IC patients

References

  1. The GreenBook chapter 28a – Shingles. July 2023
  2. SHINGRIX. Summary of Product Characteristics (GB)
  3. SHINGRIX. Summary of Product Characteristics (NI)
  4. Bastidas A, de la Serna J, El Idrissi M, et al.; for the ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial [suppl]. JAMA. 2019 July;322(2):123-133.
  5. Dagnew AF, Ilhan O, Lee WS, et al.; on behalf of the Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 September;19(9):988-1000.
  6. Vink P, Torelle JMR, Sanchez Fructuoso A, et al.; for the Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020 January;70(2):181-190.
  7. Vink P, Mignorance ID, Alonso CM, et al.; on behalf of the Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019 April;125(8):1301-1312.
  8. Berkowitz EM, Moyle G, Stellbrink HJ, et al for the Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 April;211:1279-1287.

Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

January 2024 | PM-GB-SGX-WCNT-230042